Insmed Secures EU Approval for Brensocatib – First Indication Offers Peak Revenue Potential of $5 Billion!

The biotech company Insmed (INSM) specializes in the development of medications for the treatment of rare lung diseases and aims to expand its reach from 530,000 patients to over 2 million people by 2030. The core product ARIKAYCE is expected to extend the treatment potential for lung infections caused by the Mycobacterium avium complex (MAC) from 30,000 to 250,000 patients with the Phase 3 ENCORE study anticipated in the first half of 2026. On August 12, the FDA approval for Brinsupti (Brensocatib) was granted as the second commercial product,...